Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

ts are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether experimental pain models of pain, including the capsaicin model, are accurate in predicting efficacy of novel analgesics in early clinical trials, whether the results of any Phase II trial or other study of NGX426 will be consistent with the results of the study reported in this press release, whether TorreyPines will be able to complete any potential strategic or financing transaction on terms acceptable to TorreyPines' stockholders, how the volatile economic environment will affect TorreyPines' efforts to complete a strategic or financing transaction, whether TorreyPines' cash resources will be sufficient to fund operations as planned, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical tri
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Research and Markets ... Synthetic Biology Market 2014-2018" report to their offering. ... The term synthetic biology covers the designing and engineering ... well as the redesigning of natural biological systems that ... be a form of extreme genetic engineering because it ...
(Date:7/28/2014)... PA & Boston, MA (PRWEB) July 28, 2014 ... collaboration agreements with two researchers to further develop potential ... deadly malignant brain tumor, in combination with their patented ... by ITI and Duke University, are based on the ... Chief, Division of Neurosurgery at The Preston Robert Tisch ...
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/28/2014)... July 28, 2014 The National Model ... Muncie IN, is pleased to announce that it has ... Museum of the United States Air Force. , The ... process that concluded this spring with an on-site inspection ... OH museum. , The National Museum of the ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2
... epigenetic anticancer program at Pharmion ... inhibitors - ... Significant opportunity to explore combination epigenetic therapies, BOULDER, Colo. ... and MethylGene Inc. (TSX: MYG) today announced a,research collaboration for ...
... /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: ... increased more than,35% over the first quarter of 2007 ... for the same period in the previous year. ... compared to only,$24,374 in the first half of 2006. ...
... COLUMBIA, Md., Aug. 14 Martek Biosciences,Corporation announced that ... of fiscal 2007 on September 5, 2007, at approximately ... 4:45 p.m. EDT Martek,will hold a conference call to ... with investors. The call is expected to be approximately ...
Cached Biology Technology:Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 3Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 4Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 5Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 6Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6Martek to Announce Third Quarter 2007 Results on September 5, 2007 2
(Date:7/28/2014)... Wyss Institute for Biologically Inspired Engineering at Harvard ... will be commercialized by a newly formed private ... and personalized medicine products. The announcement ... of Technology Development (OTD) and the start-up Emulate ... automated human Organs-on-Chips platform. , "This is ...
(Date:7/27/2014)... that nicotine and cotinine, a metabolite of nicotine, can ... in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK is ... ends up in the tobacco smoke. Once inhaled, it ... is activated by a variety of enzymes called Cytochrome ... nicotine can partially interfere with the activation of NNK, ...
(Date:7/27/2014)... of mayfly in the southern Western Ghats, a mountain range ... the first time that any mayfly belonging to the genus ... The new species, called Labiobaetis soldani , "is named ... to the understanding of the Ephemeroptera of Palaearctic and Oriental ... the new mayfly in the Journal of Insect Science ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2
... The discovery by Uppsala University researchers of a previously ... ways brings new potential for early diagnosis of a ... the Web edition of the American journal Proceedings ... provide new knowledge of the cause of common diseases ...
... native fishes in the Pacific Northwest are threatened or ... are expended annually on researching their populations and on ... been directed toward to the impacts of habitat alteration, ... published in the March 2009 issue of BioScience ...
... Society for Clinical and Economic Aspects of Osteoporosis and ... scientific programme for the upcoming IOF WCO- ECCEO10, a ... May 5-8, 2010. Complete programme information, online ... www.iofwco-ecceo10.org . IOF WCO-ECCEO10 will offer ...
Cached Biology News:World Congress on Osteoporosis 2010 presents outstanding scientific program 2
...
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
... Protein Extraction Reagent is a ... that means no scraping, no ... With M-PER Reagent, rapid lysis ... at room temperature, yielding 25% ...
... FailSafe™ PCR System is the only PCR ... time and every time. It provides accuracy, ... the source or the property of the ... PCR Enzyme Mix, a unique blend of ...
Biology Products: